NCT02549989

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

Single-Arm, Open-Label, Phase II Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effectiveness of LY3023414 in treating the participants type of cancer and to determine the types and severity of side effects caused by treatment with LY3023414.

Conditions

• Endometrial Cancer
• Recurrent Endometrial Cancer

Interventions

Type	Name	Description
DRUG	LY3023414	Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination

Timeline

• Start date: 2015-09-01
• Primary completion: 2022-03-23
• Completion: 2022-03-23
• First posted: 2015-09-15
• Last updated: 2023-02-22
• Results posted: 2023-02-22

Locations

6 sites across 1 country: United States